Comments
Shares of Biocon may see buying interest, as the company won a major ruling for insulin drug in the US. According to Biocon, the US District Court of New Jersey invalidated Sanofi’s patent suit against Biocon-Mylan insulin glargine product. With the key legal hurdle now removed, the company is confident of commercialising Semglee, which is under review currently by the USFDA, by 2020. The market opportunity for insulin glargine is estimated at $2.2 billion, the company said.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.